PVALB

Across TCGA pan-cancer cohorts, PVALB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PVALB data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PVALB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PVALB expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and GBM are the cancer types where PVALB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.920	0.253	.002	20	view →
LSCC	OS	Tertile	II,III,IV	0.988	0.728	.003	19	view →
GBM	DFS	Tertile	All	0.452	0.243	.007	3	view →
CCRCC	OS	Median	All	0.742	1.000	.033	2	view →
HNSC	DFS	Median	II,III,IV	0.911	0.971	.033	2	view →
UCEC	DFS	Median	All	1.000	0.921	.023	2	view →
LUAD	OS	Median	All	0.978	0.791	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PVALB–PDAC (DFS)

Open the PDAC breakdown →